Mounjaro and Wegovy on the NHS: who qualifies?

The short version

Yes, both Wegovy (semaglutide) and Mounjaro (tirzepatide) can be prescribed on the NHS for weight management — but "can be" is doing a lot of work in that sentence. Access runs through NICE eligibility criteria, referral pathways and, for much of the country, specialist weight-management services with long waits. Understanding how the system actually works saves a lot of frustrated GP appointments.

The NICE criteria in plain English

NICE — the body that decides what the NHS funds — has approved both medicines for weight management with eligibility built mainly around BMI plus weight-related health conditions. In broad terms: the higher your BMI and the more weight-related conditions you have (type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnoea, heart disease and similar), the stronger your NHS eligibility. Thresholds are adjusted for people from some ethnic backgrounds, whose health risks rise at lower BMIs.

Wegovy's NHS use has generally sat within specialist weight-management services — multidisciplinary teams you reach by referral, typically with treatment reviewed over a defined period. Mounjaro's NHS availability is being phased in more broadly, including through primary care, with the earliest phases deliberately prioritising people with the highest clinical need — the highest BMI bands combined with multiple weight-related conditions. The phasing exists because the eligible population is enormous relative to NHS capacity and supply.

Eligibility on paper vs access in practice

This is the part most articles skim. Meeting NICE criteria does not put a pen in your hand; it puts you in a queue. Specialist services have waiting lists that vary enormously by region, some areas have limited or no service provision, and phased rollouts mean many people who meet the published criteria are not yet in a cohort being treated. A GP can tell you where you sit locally — and an honest answer may involve months, not weeks.

None of this is a criticism of NHS clinicians; it is arithmetic. Millions of people meet the criteria, the medicines are expensive at scale, and services take time to build. But it explains the question we hear most: "I qualify — so why can't I get it?"

What the NHS route costs you

If you are prescribed either medicine on the NHS, you pay the standard NHS prescription charge per item in England (currently under £10), and nothing in Scotland, Wales or Northern Ireland. The medicine's actual cost to the NHS is far higher — which is exactly why access is rationed through criteria and phased rollouts.

How the NHS referral actually works

The typical journey has four stages. First, a GP appointment where your BMI, weight-related conditions and history are recorded — bring a clear picture of what you have already tried, because documented previous attempts at weight management strengthen referrals. Second, referral to your local pathway: in many areas a tiered system where specialist weight-management services sit at the level that can prescribe these medicines. Third, assessment by that service — often including dietetic and psychological input, which is genuinely useful rather than box-ticking. Fourth, prescribing and structured follow-up if treatment is agreed.

Each stage has a queue, and the stages are sequential, which is how a person who "qualifies" in January can still be untreated by autumn. If your area's rollout includes primary-care prescribing for Mounjaro, stages two and three compress — but the prioritised cohorts are reached first, in descending clinical need.

The devolved nations run their own pathway structures and rollout timing, so the picture in Scotland, Wales and Northern Ireland can differ from England's in both eligibility interpretation and waiting times — the prescription-charge advantage there is real, but so is variation in service provision. Wherever you live, arrive at the GP appointment prepared: recent weight history, previous weight-management attempts (programmes, medicines, referrals), current medicines, and any weight-related diagnoses. A well-documented ten-minute appointment moves a referral faster than three vague ones.

Special cases worth knowing about

Type 2 diabetes changes the picture: Mounjaro has a separate, longer-standing NHS route as a diabetes treatment, with its own criteria through diabetes care rather than weight-management services. People awaiting bariatric surgery are sometimes prescribed these medicines within specialist services as part of surgical pathways. And where a medicine is unavailable or unsuitable, services can consider the alternatives — which now include the newly approved tablet, Foundayo, once NICE has appraised it.

Time limits and stopping rules

NHS prescribing in specialist services has typically come with review points and, for some pathways, defined treatment durations — the service model assumes treatment is a supported phase, not an open-ended subscription. What happens at the end of a funded period varies by pathway and is evolving as rollouts mature; it is a fair question to ask at assessment, and one more reason the private route (where duration is a clinical decision between you and your prescriber) suits some people despite the cost.

How the private route differs

Private treatment through a regulated UK pharmacy works to the same licence conditions — a clinician assesses your BMI, health conditions and medicines, and prescribes only where treatment is appropriate — but without the queue. Eligibility is set by the medicine's licence rather than NHS rationing criteria, so some people who fall outside NHS cohorts (for example, a BMI of 30 without multiple comorbidities) can be treated privately where clinically suitable. The trade-off is cost: you pay for the medicine and the service. Our guide to NHS vs private costs breaks the numbers down.

One caution: "private" must still mean regulated — a GPhC-registered pharmacy and a real prescriber consultation. If a website will supply without asking about your health, it is not a shortcut; it is a red flag.

Choosing your route

A sensible sequence: check your position with your GP if you think you meet NHS criteria and can wait; consider regulated private treatment if speed matters, the NHS route is not available where you live, or you sit outside the current NHS cohorts; and treat any route that skips clinical assessment as disqualified by definition. If you are unsure where you fall, a free consultation with a UK-registered clinician can establish your eligibility on both tracks — and our weight-management guides cover the treatments themselves in depth.